Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (September 2020)
18 slides from Moleculin Biotech's investor presentation, Sep 14, 2020
Slide 1: Moleculin: Developing ground-breaking therapies for highly resistant cancers and viruses
= c wv Moleculin Developing ground-breaking therapies for highly resistant cancers and viruses September 11, 2020 Public Presentation
Slide 2: Disclaimer
Disclaimer Al statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe; “
Slide 3: Highly Experienced Leadership
Slide 4: Management Team
nagement Team Walter Klemp, Chairman, President & CEO Don Picker, PhD. Chief Science Officer Jonathan P. Foster, CPA, CCMA EvP & CFO RobertShepard, ‘MD, FACP Chief Medical Officer ‘Sandrasilberman, ‘MD & PhD Chief Medical Officer New Products Selected Prior Experience soliton ZENO EPG a ct < SYNERGY
Slide 5: Science Advisory Board
Pancreatic James ‘Abbruzzese, MD DANA-FARBER W Duke Universi ‘School of Medicine Science Advisory Board Hematology rps tons ‘Marty Tallman, MD Memorial Sloan Kettering ou GeoRSIA EANCeR Conver Virology Richard Whitley, “DD HongboZhai, ae
Slide 6: Non-cardiotoxic anthracycline, STAT3 inhibitor, antimetabolites
Non-cardiotoxic anthra STATS Inhibitor Antimetabolites — cancers and viruses World class collaboration Highly experienced team Exclusive IP/Fast Track
Slide 7: Immune/Transcription Modulators and Antimetabolites
immu Modula inhibitor Key cancer and viral we1066 Antimetabolites / Glycosylation Inhibitor Prodrug of glucose decoy enables drug-like properties Disruption of metabolisms - relevant to certain cancers and viruses \Moleculin
Slide 8: Drug candidates and indications
Dru; re 7 AML Lung Mets | orc | GBM Bocici GBM WP1122 Pancreatic COvID-19 HIV Zika/Dengue SMoleculin
Slide 9: Leading Partnerships, Collaborations
Leading Partnerships, Collaborations: REGA INSTITUTE KU LEUVEN Dr. Dominique Schols of the Rega Institute has joined the Moleculin Science Advisory Board Pharmiceaiteals ‘nc at ‘Annamycin AML tral in EU, Sublicenses for eels ners out cae ae WE Physician sponsored pediatric “allcomers” bain tumor tri
Slide 10: Antimetabolites/Glycosylation Inhibitor Phase and Activity
Antimetabolites/ Glycosylation Inhibitor SMoleculin Phase 1 Activity Phase 2 wens MDAnderson wens:
Slide 11: Antimetabolites/Glycosylation Inhibitor Phase and Activity
Antimetabolit Glycosylation Inhibitor SMolecutin Phase 1 Activity Phase 2 wens: = MD Anderson GincerCenter GP Mmocunt EMORY
Slide 12: Key Developments: drug candidates in clinical trials
Key Developments 3 drug candidates in 5 clinical trials Next Generation Anthracycline - Annamy: Is) + Positive interim safety and efficacy data in US and Europe AML Trials + 45% efficacy in 11 relapsed AML patients treated at/or above 120 mg/m* (1 Ci, 3 PRs, 1 BTB); clearing circulating blasts + No
Slide 13: Antimetabolites development and next steps
dependent ‘ro stusies SMoleculin led antimetabottes ‘under indication Submit NDICTA ‘COVID-19 ‘Submit INOICTA for other vinuses bem 13
Slide 14: Additional Potential 2020 Value Inflection Points
Additional Potential 2020 Value Inflection Points STATS Inhibitors MD Anderson GBM Phase 1 Data & Continues Emory Pesiatic ran Tumor Phase Begins ll sO We1066 and Ration GBM Tal proved & Tal ens File WP1220 CTCL Phase 2 Trial IND/CTA or Strategic Partner SMolecutin “
Slide 15: Financial Review
al Revi Financi
Slide 16: Financial Statement Summary
Financial Statement Summary In thousands, except for share and per share di Forthe 6 mos outstanding 3072020 (Unaudited) (Unaudited) ‘Statement of Operations Data F Ne Revenue + "Capital efficient’ Research and development stt013 S855 approach General and adminsiratve and depreciation estt 3561 it L
Slide 17: Various Sources of Financing
Various Sources of Fin cin Opportunistic Approach + Approx. $20 million raised 2019; $17 million YTD 2020 + Three analysts have reported on MBRX~ Roth, Maxim, & Opco + Overnight and intraday deals + $15 million ATM — Opco + Equity Line - Lincoln Park Capital + Successful out-licensing of technology
Slide 18: Non-cardiotoxic anthracycline, STAT3 inhibitor, antimetabolites
Non-cardiotoxic anthra STATS Inhibitor Antimetabolites — cancers and viruses World class collaboration Highly experienced team Exclusive IP/Fast Track
Moleculin Biotech — Investor Presentation (September 2020) on 6ix